Delta-Fly Pharma
4598.TTSE GROWTHPharmaceutical
Filed as Delta-Fly Pharma,Inc. (2022-06–2026-06)
Major holders (5%+) · 4
| Holder | Stake |
|---|---|
| Evo Fund | 16.03% |
| SBI SECURITIES Co., Ltd. | 8.45% |
| Kiyoshi Eshima | 6.18% |
| Arcus Investment Limited Director/Executive Director Edward Cartwright | 5.20% |
Each holder's own ratio from its most recent large-shareholding report.
Former and minor holders (below 5%) · 8
| Morgan Stanley MUFG Securities Co., Ltd. | 3.90% |
| J.P. Morgan Securities LLC | 2.00% |
| JPMorgan Securities Japan Co., Ltd. | 0.54% |
| J.P. Morgan Securities plc | 0.46% |
| Kyoko Eshima | 0.21% |
| J.P. Morgan Prime Inc. | 0.06% |
| Evolution Capital Management LLC | 0.00% |
| Macquarie Bank Limited | 0.00% |
Ownership history · 65
| Holder | Ratio | Change |
|---|---|---|
| Kyoko Eshima2024-09-30 · amended | 0.30% | -0.16pp |
| Kiyoshi Eshima2024-09-30 · amended | 10.71% | -5.49pp |
| Kyoko Eshima2024-09-30 · amended | 0.46% | new |
| Kiyoshi Eshima2024-09-30 · amended | 16.20% | new |
| SBI SECURITIES Co., Ltd.2024-02-06 | 4.46% | new |
Each holder in 5% reports, joint holders included. Purpose is classified from the filed text.